搜索
Nuvation Bio Inc
NUVB添加自选
4.320USD
-0.395-8.37%
收盘 05/15, 16:00（美东）报价延迟15分钟
1.50B总市值
亏损市盈率 TTM
查看详细走势图
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-8.37%
5天
-9.81%
1月
-10.19%
6月
-11.11%
今年开始到现在
-51.79%
1年
+91.15%
TradingKey Nuvation Bio Inc股票评分
单位: USD 更新时间: 2026-05-15操作建议
Nuvation Bio Inc当前公司基本面数据相对健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名78/382位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价12.30。中期看，股价处于下降通道。近一个月，市场表现非常差，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Nuvation Bio Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
看空
Nuvation Bio Inc亮点
亮点风险
Nuvation Bio Inc. is a global biopharmaceutical company. The Company is engaged in tackling the unmet needs in oncology by developing differentiated and therapeutic candidates. Its programs include taletrectinib (ROS1 inhibitor), safusidenib (mIDH1 inhibitor), NUV-1511 (drug-drug conjugate), and NUV-868 (BET inhibitor). The Company's Taletrectinib is an oral, potent, central nervous system-active, selective, ROS1 inhibitor specifically designed for the treatment of patients with ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC). Safusidenib is a novel, oral, potent, brain penetrant, targeted inhibitor of mutant isocitrate dehydrogenase 1(mIDH1). NUV-1511, a clinical-stage drug-drug conjugate (DDC), fuses a targeting agent to a widely used chemotherapy agent. Its NUV-868 is a BD2-selective, oral, small molecule bromodomain and extra-terminal (BET) inhibitor that inhibits BRD4.
业绩增长期
公司处于发展阶段，最新年度总收入62.90M美元
利润高增长
公司净利润处于行业前列，最新年度总收入62.90M美元
估值低估
公司最新PE估值-10.13，处于3年历史低位
机构减仓
最新机构持股228.36M股，环比减少12.58%
乔尔·格林布拉特持仓
明星投资者乔尔·格林布拉特持仓，最新持仓市值31.27K
分析师目标
根据
11
位分析师
买入
评级
12.300
目标均价
+157.32%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Nuvation Bio Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Nuvation Bio Inc简介
Nuvation Bio Inc. is a global biopharmaceutical company. The Company is engaged in tackling the unmet needs in oncology by developing differentiated and therapeutic candidates. Its programs include taletrectinib (ROS1 inhibitor), safusidenib (mIDH1 inhibitor), NUV-1511 (drug-drug conjugate), and NUV-868 (BET inhibitor). The Company's Taletrectinib is an oral, potent, central nervous system-active, selective, ROS1 inhibitor specifically designed for the treatment of patients with ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC). Safusidenib is a novel, oral, potent, brain penetrant, targeted inhibitor of mutant isocitrate dehydrogenase 1(mIDH1). NUV-1511, a clinical-stage drug-drug conjugate (DDC), fuses a targeting agent to a widely used chemotherapy agent. Its NUV-868 is a BD2-selective, oral, small molecule bromodomain and extra-terminal (BET) inhibitor that inhibits BRD4.
公司代码NUVB
公司Nuvation Bio Inc
CEOHung (David T)
网址https://www.nuvationbio.com/
相关品种
